Greenphire has announced the launch of EnvisiX to address the budgeting challenges experienced by global sponsors and CROs during study start-up. The new budget development solution aims to streamline trial initiation for sponsors and CROs and eliminate guesswork during the budgeting process to deliver a smarter, more efficient workflow.
EnvisiX integrates with eClinicalGPS, Greenphire’s site payment solution, enabling simplicity and efficiency throughout a trial from budget creation and negotiation to management, execution, and tracking of global investigator grants.
“Greenphire is dedicated to engineering workflow and data solutions that transform business processes, reducing administrative burden and improving process effectiveness at each step of the clinical trial,” said Jim Murphy, Greenphire CEO. “With EnvisiX, stakeholders gain visibility and control over historically manual and fragmented budget build and negotiation workflows, ensuring improved speed and accuracy along the way.”
EnvisiX will enable sponsors and CROs to:
“For years, sponsors and CROs have expressed dissatisfaction with their study start-up processes. We have developed EnvisiX as a direct response to frustrations with the current workflows and solutions available in the market today,” said Kyle Cunningham, Chief Product Officer at Greenphire. “Our mission was to ensure that EnvisiX provides our customers with a streamlined and user-friendly experience for building a budget and ultimately to enable maximized confidence, defensibility and end-to-end efficiency via a direct integration and feedback loop with eClinicalGPS, the industry’s leading site payment solution.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.